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Purpose: To determine the outcome of needling with adjunctive 5-
ﬂuorouracil (5-FU) in patients with a failing Ahmed glaucoma
valve (AGV) implant, and to identify predictors of long-term
intraocular pressure (IOP) control.
Methods: A prospective observational study was performed on
consecutive patients with medically uncontrolled primary open-
angle glaucoma (POAG) with AGV encapsulation or ﬁbrosis and
inadequate IOP control. Bleb needling with 5-FU injection (0.1mL
of 50mg/mL) was performed at the slit-lamp. Patients were
examined 1 week following the needling, and then at months 1, 3,
and 6. Subsequent follow-up visits were scheduled at 6-month
intervals for at least 2 years. Needling with 5-FU was repeated no
more than twice during the ﬁrst 3 months of the follow-up. Pro-
cedure outcome was determined on the basis of the recorded IOP
levels.
Results: Thirty-six patients with an encapsulated or ﬁbrotic AGV
underwent 67procedures (mean 1.86±0.83). Complete success,
deﬁned as IOPr18mm Hg without medications, was obtained in
25% at 24 months of observation. The cumulative proportion of
cases achieving either qualiﬁed (ie, IOPr18mm Hg with medi-
cations) or complete success at 24 months of observation was
72.2%. In a univariate Cox proportional hazards model, age was
the only variable that independently inﬂuenced the risk of failing 5-
FU needling revision. Fourteen eyes (38.8%) had a documented
complication.
Conclusions:Needling over the plate of an AGV supplemented with
5-FU is an eﬀective and safe choice in a signiﬁcant proportion of
POAG patients with elevated IOP due to encapsulation or ﬁbrosis.
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Glaucoma drainage implants have become a valuabletool in the surgical management of refractory glau-
coma.1,2 They are eﬀective in reducing intraocular pressure
(IOP) and are especially useful when there is high risk of
failure for a ﬁltering procedure.3,4
The Ahmed glaucoma valve (AGV) is a widely used
glaucoma drainage implant. To reduce the occurrence of
severe postoperative hypotony, this valve is equipped with
internal resistance that reduces the need for intraoperative
modiﬁcations.5 However, ﬁbrosis or encapsulation around
the valve reservoir may occur, with formation of a Tenon’s
cyst. This early postoperative complication may increase
distal outﬂow resistance and result in IOP elevation and
subsequent valve failure.6 An encapsulated bleb is one that
has been walled-oﬀ by the Tenon’s capsule, resulting in a
rigid elevation of the mobile conjunctival tissue. Vice versa,
a ﬁbrotic bleb, which results from the adherence of the
conjunctival and Tenon’s tissues to the underlying episclera
surrounding the valve plate, is characterized by a ﬂat
appearance. Fibrosis or encapsulation of the ﬁltering bleb
might compromise the outcome of trabeculectomy.
Needling revision of the ﬁltering bleb, with or without
adjunctive 5-ﬂuorouracil (5-FU) or mitomycin C, is fre-
quently used to improve ﬂow through an encapsulated or
ﬁbrotic ﬁltering bleb.7,8 We have undertaken this pro-
spective observational study to determine the outcome of
needling with adjunctive 5-FU in patients with a failing
AGV implant, and to identify predictors of long-term IOP
control.
MATERIALS AND METHODS
The study included consecutive patients with medically
uncontrolled primary open-angle glaucoma (POAG) with
valve encapsulation and inadequate IOP control after a
period of at least 6 months from uncomplicated AGV
implantation (Model S2; New World Medical, Rancho
Cucamonga, LA) in the superotemporal quadrant. All
patients had at least 1 failed trabeculectomy with intra-
operative use of mitomycin C before the insertion of the
valve. Qualiﬁed patients showed a patent tube in the ante-
rior chamber (AC) as determined by slit-lamp examination.
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Patients were excluded if they had previous or current
inﬂammatory ocular conditions, diabetes mellitus, or a
history of previous ocular surgery, with the exception of
uncomplicated cataract surgery or trabeculectomy at least
12 months before enrollment.
The study adhered to the tenets of the Helsinki Dec-
laration. Written informed consent was obtained from all
participants before any study procedures or examinations
were performed. All AGV implantations and subsequent
interventions were performed in a single academic center by
an experienced glaucoma surgeon (L.Q.). The original
technique has been described elsewhere.9
Bleb needling was performed at the slit-lamp using a
standardized technique by the same surgeon (L.Q.). Patients
were instructed to look to the direction opposite the quad-
rant where the AGV was located. Amethocaine 1.0%,
phenylephrine 2.5%, chloramphenicol 0.5%, and povidone-
iodine 5% drops were instilled before needling. A 28-G
needle attached to a 1-mL syringe was used to enter the
subconjunctival space adjacent to the reservoir on the tem-
poral side. The needle was introduced underneath the con-
junctiva near the reservoir and was advanced a short dis-
tance (approximately 5 to 6mm). The tip of the needle was
turned toward the surface of the AGV to penetrate the
ﬁbrous capsule or the Tenon’s cyst, and several tears were
made in the capsule. Due attention was given to avoid
inadvertent perforation of the overlying conjunctiva and
subconjunctival blood vessels. Reestablishment of aqueous
ﬂow was documented as an immediate increase in bleb size.
If recovery of ﬂow was not observed, or if a previous nee-
dling attempt had proven ineﬀective, a diﬀerent entry site
into the subconjunctival space was used. A subconjunctival
injection of 0.1mL of 50mg/mL 5-FU solution was carried
out at the needling site. Following a negative or minimally
positive Seidel test, the eye was patched until the next
morning with tobramycin antibiotic ointment. Patients were
placed on topical dexamethasone 6 times daily for 1 month
and then tapered as clinically indicated for 3 months.
Topical chloramphenicol was given 4 times daily for a week.
Patients were examined 1 week following the needling
procedure, and then at months 1, 3, and 6. Subsequent
follow-up visits were scheduled at 6-month intervals for a
minimum of 2 years. Additional visits were performed at
the discretion of the surgeon. At each follow-up visit,
Snellen best corrected visual acuity was determined and
Goldmann sitting applanation tonometry was performed.
A slit-lamp examination was performed and possible nee-
dling complications were documented. Bleb morphology
was assessed and further needling and/or 5-FU injection
was considered in case of active ﬁbrosis, or failure to ach-
ieve the desired target IOP. Needling with 5-FU was
repeated no more than twice during the ﬁrst 3 months of
follow-up.
Procedure outcome was determined on the basis of the
recorded IOP levels. Study patients were classiﬁed as
“nonresponders” if they had sustained (Z2 visits) IOP of
>18mm Hg, “qualiﬁed success” if IOP was r18mm Hg
with glaucoma medication, and “complete success” if IOP
was r18mm Hg without glaucoma medications. A uni-
variate Cox proportional hazard model was used to test the
association between demographic characteristics and clin-
ical features and procedure outcome. Results are expressed
as hazard ratios with 95% conﬁdence intervals. Paired t test
was used to compare IOP levels at each timepoint and
baseline. The statistical signiﬁcance was set at 0.05 for a
bilateral test. Analyses were carried out using the SAS
Software, version 9.2 (SAS Institute Inc., Cary, NC).
RESULTS
Thirty-six consecutive adult POAG patients with an
encapsulated AGV implant were enrolled. All patients com-
pleted the study procedures and were eligible for
analysis. Table 1 summarizes patient and intervention char-
acteristics. Sixty-seven needling procedures were performed
(mean number±SD=1.86±0.83 needlings/eye). Fifteen
patients underwent a single needling, 11 and 10 patients had 2
and 3 procedures, respectively. Four (11.1%), 25 (69.4%),
and 7 (19.4%) patients underwent 1, 2, and 3 previous sur-
geries, respectively. All patients were pseudophakic.
Treatment Outcome
The criterion of complete success (ie, IOPr18mm Hg
without medications) was met in all patients at the ﬁrst week
postneedling visit. Complete success was maintained in 63.9%,
33.3%, 27.8%, 25.0%, 25.0%, and 25.0% at 1, 3, 6, 12, 18,
and 24 months of observation, respectively. Glaucoma medi-
cations had to be reinstated for adequate IOP control in 23
patients (63.9%) within 3 months of the needling revision
procedure. After this initial phase, the proportion of patients
with complete success appeared to stabilize at 27.8% after 6
months, and 25% from month 12 onward. The cumulative
proportion of cases achieving either qualiﬁed or complete
success at 1, 3, 6, 12, 18, and 24 months of observation was
100%, 97.8%, 86.1%, 75.0%, 75.0%, and 72.2%, respectively.
Figure 1 presents the proportion of patients with no response
and qualiﬁed success/no response over the study period.
IOP Over Time
IOP levels signiﬁcantly increased in the early period
following needling, from 10 (SD=3.4)mm Hg at 1 week to
16.9 (SD=4.5)mm Hg at month 6. After this period, the
tendency of IOP to increase subsided (Table 2).
Factors Influencing Treatment Efficacy
In a univariate Cox proportional hazards model, age
was the only variable that independently inﬂuenced the risk
of failing needling revision and 5-FU treatment, with a 10
times greater risk of failure (hazard ratio=10.4; 95%
conﬁdence interval, 1.8-60.1; P=0.009) for each 10-year
age increase (Table 3). It should be stressed, however, that
TABLE 1. Patient and Intervention Characteristics
Age (y)





Bleb type [N (%)]
Encapsulated 14 (38.9)
Fibrous 22 (61.1)
Months from AGV intervention
Mean (SD) 20.1 (12.9)
Min-max 6-60
IOP (mm Hg)
Mean (SD) 29.5 (3.8)
Min-max 24-37
AGV indicates Ahmed glaucoma valve; min-max, minimum and max-
imum values.
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“nonresponders” represent a subgroup of participants who
failed both needling with 5-FU and medical treatment.
Male sex was found to be a risk factor of borderline
signiﬁcance (P=0.05) for not achieving complete success.
Needling Revision Complications
After a total of 67 needling procedures performed, 14
eyes (38.8%) had a documented complication (Table 4). Of
these, 12 were minor and resolved spontaneously. The most
frequent complication was subconjunctival hemorrhage (8
cases), and aqueous leakage from the needling site, which was
present in 4 cases after 2 to 3 needling revisions. In 2 cases,
aqueous leakage was associated with choroidal detachment
and/or signiﬁcant AC shallowing. The interventions to
address these complications included administration of
aqueous suppressants, compressive bandages, and curtailing
topical steroids until the leak stopped. Conjunctival sutures
and AC reformation with viscoelastic were required in these
2 cases after 1 week of conservative treatment.
DISCUSSION
Implantation of an AGV has been proven an eﬀective
method for treating refractory glaucoma, with long-term
success rates ranging from 49% to 83.6%.10–12 The long-
term success of glaucoma drainage devices depends on the
characteristics of the ﬁbrotic reaction surrounding the valve
reservoir in the episcleral space. Previous reports have
shown that plate size, conﬁguration, and composition can
have an impact on long-term outcome.6
Encapsulation is one of the main reasons for glaucoma
valve failure.13 An encapsulated cyst (also called Tenon’s
cyst) develops when Tenon’s capsule adheres to the epis-
clera forming a high, domed, smooth, 2-layered bleb.14–16
The encapsulated bleb is impervious to aqueous humor
outﬂow and leads to IOP elevation. The proliferation of
ﬁbrous tissue around the implant plates is another block to
aqueous humor diﬀusion.17 It is widely agreed that distal
resistance is the primary mechanism for IOP elevation.6
There is also evidence to suggest that proinﬂammatory
cytokines are found at higher levels in the aqueous of eyes
with encapsulated blebs and elevated IOP.18 Therefore,
wound modulation and adequate anti-inﬂammatory treat-
ment may help control the ﬁbrotic changes that jeopardize
the success of bleb-dependent glaucoma operations.
Needling revision of the ﬁltering bleb, with or without
antimetabolites, is frequently used to restore ﬂow through
encapsulated or ﬁbrotic blebs.7,8 Nonetheless, evidence of
FIGURE 1. Failure-free survival in 36 patients undergoing 5-fluorouracil needling revision of encapsulated blebs over a 48-month follow-
up period.
TABLE 2. Intraocular Pressure and Topical Antiglaucoma Medication Use Over Time
IOP (mm Hg) No. Antiglaucoma Medications
Timepoint No. Patients Mean (SD) Min-Max P* Nw Mean (SD) Min-Max
Baseline 36 29.5 (3.7) 24-37 — 0 0 0
1wk 36 10.0 (3.4) 4-16 <0.0001 0 0 0
1mo 36 14.2 (2.8) 10-22 <0.0001 13 1.3 (0.6) 1-3
3mo 36 16.0 (3.8) 10-24 <0.0001 24 2.0 (1.0) 1-4
6mo 35 16.9 (4.5) 10-26 <0.0001 25 2.2 (1.0) 1-4
12mo 31 16.4 (4.5) 10-26 <0.0001 22 2.2 (0.9) 1-4
18mo 27 15.4 (2.8) 11-24 <0.0001 22 2.0 (1.0) 1-4
24mo 26 15.4 (2.4) 10-18 <0.0001 17 1.9 (0.6) 1-3
*The t test for the comparison of each timepoint versus baseline.
wNumber of patients using topical antiglaucoma medications.
IOP indicates intraocular pressure; min-max, minimum and maximum values.
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the eﬃcacy of this procedure is contradictory. Depending
on classiﬁcation criteria and length of follow-up, the
reported success rate of needling revision of a ﬁltering
trabeculectomy bleb varies between 49% and 96%.19 Long-
term success can be inﬂuenced by numerous factors such as
previous surgeries, ethnicity, etiology of glaucoma, and
surgical technique.19–21 Moreover, Costa et al22 showed in a
randomized trial that treatment with aqueous suppressants
and digital massage is superior to needling without anti-
metabolites in patients with encapsulated trabeculectomy
blebs after a follow-up of 9.6 months. Hence, there is yet no
consensus on the eﬀectiveness of needling revisions of
glaucoma drainage implants, with or without adjunctive
antimetabolites. Few case series have been published so
far,23,24 but information from controlled trials is not
available.
Our prospective observational study evaluated 36
patients showing the maintenance of either complete or
qualiﬁed success in 72% of cases over a 48-month follow-up
period. The ﬁndings of the present study suggest that the
use of 5-FU during needling revision favorably inﬂuences
the outcome of IOP control after AGV implantation. In
our study, 5-FU needling in eyes with AGV implants was
able to reestablish control of IOP, with or without addi-
tional medications, in 76% of eyes over a 24-month follow-
up period.
Our clinical impression was that needling was most
likely to succeed if an immediate increase in bleb size was
noticed during the needling procedure. Our data suggest
that the procedure was equally eﬀective for encapsulated
and ﬁbrous blebs. Moreover, no long-term side eﬀects of
antimetabolites were observed in either the conjunctiva or
the cornea.
Older age was identiﬁed as a risk factor for failure of
the needling procedure. One potential explanation may be
the fact that older age is a surrogate for longer disease
duration, and thus greater cumulative exposure to anti-
glaucoma drugs and preservatives. There is evidence that
exposure to antiglaucoma medications correlates with
poorer long-term survival of glaucoma ﬁltering proce-
dures.25 Our data indicate that male sex may be a risk
factor for not achieving complete success. However, this
result was of marginal signiﬁcance (P=0.05) and larger
studies are needed to conﬁrm this ﬁnding.
Our study has some limitations. Neither a control
group of patients receiving only medical therapy nor a
control group undergoing needling without adjunctive 5-
FU injection was employed. Therefore, the exact eﬃcacy of
needling with adjunctive 5-FU per se cannot be determined.
This limitation of design was diﬃcult to avoid, as clinical
judgement and routine practice mandated the use of med-
ication and needling with 5-FU. It is clear, however, that
our procedure is eﬃcacious in a signiﬁcant proportion of
patients (25%) who achieved medication-free IOP control
over a 2-year period. Another limitation of our study is that
these results may not be entirely applicable to patients
implanted with other glaucoma drainage devices or even
diﬀerent versions of the AGV.
In conclusion, this study demonstrates that needling
over the plate of an AGV supplemented with 5-FU is an
eﬀective choice in a proportion of POAG patients with
elevated IOP due to encapsulation or ﬁbrosis. The proce-
dure, performed as many times as deemed necessary, can
lessen the ﬁbrotic changes that threaten the long-term
success of an AGV. Performed at the slit-lamp, needling
revision is a relatively simple and safe procedure that
reinstates aqueous ﬂow in a signiﬁcant proportion of
POAG patients. More information from controlled studies
is needed in the future to elucidate the success of this pro-
cedure in other glaucoma types with worse prognosis.
TABLE 3. Factors Influencing the Risk of Needling and 5-Floruouracil Treatment Failure
No Response Qualiﬁed Success or No Response
Characteristics HR (95% CI) P HR (95% CI) P
Bleb
Encapsulated (reference) 1 — 1 —
Fibrous 7.1 (0.9-56.1) 0.063 2.0 (0.9-4.6) 0.084
Time from AGV intervention (for each 5mo increase) 0.9 (0.6-1.2) 0.366 1.0 (0.8-1.1) 0.557
IOP pre-5FU needling (for each 5mm Hg increase) 0.9 (0.38-2.2) 0.822 0.7 (0.4-1.2) 0.259
Age (for each 10 y increase) 10.4 (1.8-60.1) 0.009 1.5 (0.7-3.4) 0.930
Sex
Female (reference) 1 — 1 —
Male 1.6 (0.4-5.7) 0.466 2.2 (1.0-4.8) 0.050
Previous surgeries
1 (reference) 1 — 1 —
2 0.4 (0.1-2.1) 0.293 1.1 (0.3-3.7) 0.904
3 0.92 (0.18-6.57) 0.924 0.8 (0.2-3.8) 0.808
AGV indicates Ahmed glaucoma valve; CI, conﬁdence interval; HR, hazard ratio.



















2 Nil (resolved in 1-2wk)
AC indicates anterior chamber.
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